X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
ALEMBIC PHARMA Quarterly Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA Quarterly Results   (APLL)

Here are the latest quarterly results of ALEMBIC PHARMA. For more details, see the ALEMBIC PHARMA financial fact sheet and ALEMBIC PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.

Excel Export | Annual Financial Info | Result Scoreboard

ALEMBIC PHARMA Quarterly Results

No. of Mths
Qtr. Ending
3
Sep-15
*
3
Dec-15
*
3
Mar-16
*
3
Jun-16
*
3
Sep-16
*
3
Dec-16
*
3
Mar-17
*
3
Jun-17
*
8-Qtr Chart
Click to enlarge
Net Sales Rs m10,0889,2176,2667,2808,7947,7707,4146,482 
Other income Rs m1282645292 
Turnover Rs m10,0889,2456,2927,2848,7997,7727,4226,484 
Expenses Rs m6,3275,3714,8335,7117,0166,3166,0865,468 
Gross profit Rs m3,7643,8451,4281,5711,7411,4761,3471,014 
Depreciation Rs m133217244194206211218218 
Interest Rs m7101311108189 
Profit before tax Rs m3,6243,6461,1981,3701,5301,2581,119789 
Tax Rs m735951286333332393165155 
Profit after tax Rs m2,8892,6959121,0371,198866954634 
Gross profit margin %37.341.722.821.619.819.018.215.6 
Effective tax rate %20.326.123.924.321.731.214.719.6 
Net profit margin %28.629.214.614.213.611.112.99.8 
Diluted EPS Rs 15.3 14.3 4.8 5.5 6.4 4.6 5.1 3.4  
Diluted EPS (TTM) Rs 26.5 37.1 38.2 40.0 31.0 21.3 21.5 19.4  
 Subscriber Feature                  
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Annual Reports, Regulatory Filings, Equitymaster

More Pharmaceuticals Company Quarterly Results:   FDC LTD.  DISHMAN PHARMA  AJANTA PHARMA  INDOCO REMEDIES  DIVIS LABORATORIES  

Compare ALEMBIC PHARMA With:   FDC LTD.  DISHMAN PHARMA  AJANTA PHARMA  INDOCO REMEDIES  DIVIS LABORATORIES  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 20, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS